Research programme: antibody drug conjugates- Siamab TherapeuticsAlternative Names: Anti-glycan antibodies; Anti-Neu5Gc antibodies - Sialix; Monoclonal antibody drug conjugate targeting sialyl antigen; Monoclonal antibody drug conjugate targeting TACA1; ST1 antibody drug conjugate programme
Latest Information Update: 19 Sep 2016
At a glance
- Originator Sialix
- Developer Massachusetts General Hospital; Siamab Therapeutics
- Class Antineoplastics; Drug conjugates
- Mechanism of Action Polysaccharide inhibitors; Tumour-associated carbohydrate antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
- Research Cancer